antisense oligonucleotides (ASOs
Jun 10, 2025
Amylyx’s AMX0114 Fast Tracked by FDA for ALS; Cellectar’s Iopofosine I 131 Granted FDA Breakthrough in Waldenstrom Macroglobulinemia; YolTech’s YOLT-101 Clears FDA IND for Familial Hypercholesterolemia; Oncovita’s MVdeltaC Gets FDA Orphan Tag for Pleural Mesothelioma; Merck’s ENFLONSIA Approved for RSV Prevention in Infants
Amylyx Pharmaceuticals Receives FDA Fast Track Designation for AMX0114 in ALS Amylyx Pharmaceuticals announced that the FDA has granted Fast Track designation to its investigational antisense oligonucleotide (ASO), AMX0114, for the treatment of amyotrophic lateral sclerosis (ALS). The candidate targets calpain-2...
Read More...
Oct 23, 2018
Notizia
Novartis comes up with an answer for breast cancer with PI3K drug alpelisib Novartis comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for PIK3CA mutated HR+/HER2- advanced breast cancer, BYL719 plus fulvestrant nearly doubled the progressio...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
